Alex Chapman - Atara Biotherapeutics Vice Relations
| ATRA Stock | USD 11.47 0.86 8.11% |
Executive
Alex Chapman is Vice Relations of Atara Biotherapeutics
| Address | 2380 Conejo Spectrum Street, Thousand Oaks, CA, United States, 91320 |
| Phone | 805 623 4211 |
| Web | https://www.atarabio.com |
Atara Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5748) % which means that it has lost $0.5748 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.1486) %, meaning that it created substantial loss on money invested by shareholders. Atara Biotherapeutics' management efficiency ratios could be used to measure how well Atara Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.92, whereas Return On Tangible Assets are forecasted to decline to (1.75). At present, Atara Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.1 M, whereas Non Current Assets Total are forecasted to decline to about 44.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matthew Beck | Hookipa Pharma | N/A | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| FACC FAHA | Cadrenal Therapeutics, Common | 66 | |
| Vladimir Vexler | Coherus BioSciences | 66 | |
| Cheston Turbyfill | Coherus BioSciences | N/A | |
| Ellen Cavaleri | Lyra Therapeutics | N/A | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Carlos Carillo | SAB Biotherapeutics | N/A | |
| MRCP MD | Coherus BioSciences | 55 | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| Roman Necina | Hookipa Pharma | 56 | |
| Ronan JD | Lyra Therapeutics | 51 | |
| Richard MD | Lyra Therapeutics | 61 | |
| Theresa Lavallee | Coherus BioSciences | 58 | |
| Jeffrey Cole | Cadrenal Therapeutics, Common | N/A | |
| John Bishop | Lyra Therapeutics | 62 | |
| Robert MD | Lyra Therapeutics | N/A | |
| Mark Conley | SAB Biotherapeutics | N/A | |
| Paul Reider | Coherus BioSciences | 54 | |
| Michael Chen | Coherus BioSciences | N/A | |
Management Performance
| Return On Equity | -20.15 | ||||
| Return On Asset | -0.57 |
Atara Biotherapeutics Leadership Team
Elected by the shareholders, the Atara Biotherapeutics' board of directors comprises two types of representatives: Atara Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atara. The board's role is to monitor Atara Biotherapeutics' management team and ensure that shareholders' interests are well served. Atara Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atara Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rajani MD, Senior Officer | ||
| Eric Hyllengren, Executive Officer | ||
| Jakob MD, Ex RD | ||
| Kerry Daly, Head Communications | ||
| Jill Henrich, Executive Quality | ||
| Utpal MBA, Ex CFO | ||
| Alex Chapman, Vice Relations | ||
| Anhco Nguyen, Executive Officer | ||
| Manher MD, Executive Officer | ||
| Amie Krause, Chief Officer | ||
| Charlene Banard, Chief Officer | ||
| Amar Murugan, Executive Officer | ||
| Dan Maziasz, Executive Officer | ||
| Joseph Newell, Executive Vice President Chief Technical Operations Officer | ||
| Pascal DVM, CEO President |
Atara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Atara Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -20.15 | ||||
| Return On Asset | -0.57 | ||||
| Profit Margin | (2.90) % | ||||
| Operating Margin | (0.62) % | ||||
| Current Valuation | 43.82 M | ||||
| Shares Outstanding | 5.76 M | ||||
| Shares Owned By Insiders | 22.15 % | ||||
| Shares Owned By Institutions | 50.82 % | ||||
| Number Of Shares Shorted | 636.28 K | ||||
| Price To Earning | (4.50) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.32) | Revenue Per Share 12.263 | Quarterly Revenue Growth 28.927 | Return On Assets (0.57) | Return On Equity (20.15) |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.